Zymergen Announces Launch of Initial Public Offering
April 14 2021 - 6:32AM
Zymergen Inc. (“Zymergen”), one of the world’s foremost
biofacturing companies, today announced that it has launched the
roadshow for the initial public offering (“IPO”) of 13,600,000
shares of its common stock. The initial offering price is expected
to be between $28 and $31 per share. The underwriters of the
offering will also have a 30-day option to purchase from Zymergen
up to an additional 2,040,000 shares of its common stock. Zymergen
has applied to list its common stock on the Nasdaq Global Select
Market under the symbol "ZY."
J.P. Morgan and Goldman Sachs & Co. LLC are acting as lead
book-running managers for the offering. BofA Securities, Cowen and
UBS Investment Bank are acting as book-running managers. Lazard is
acting as co-manager.
The offering will be made only by means of a prospectus. Copies
of the preliminary prospectus relating to this offering, when
available, may be obtained from: J.P. Morgan Securities LLC,
Attention: Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717 or by telephone at 866-803-9204 or by email at
prospectus-eq_fi@jpmorganchase.com; or Goldman Sachs & Co. LLC,
Attention: Prospectus Department, 200 West Street, New York, NY
10282, by telephone at (866) 471-2526 or by email at
prospectus-ny@ny.email.gs.com. Copies of the final prospectus, when
available, related to the offering will be available at
www.sec.gov.
A registration statement, including a preliminary prospectus,
relating to these securities has been filed with the U.S.
Securities and Exchange Commission but has not yet become
effective. These securities may not be sold, nor may offers to buy
be accepted, prior to the time the registration statement becomes
effective. This press release shall not constitute an offer to sell
or the solicitation of an offer to buy these securities, nor shall
there be any sale of these securities in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About ZymergenZymergen is a biofacturing
company using biology to reimagine the world. Zymergen partners
with nature to design, develop and manufacture bio-based
breakthrough products that deliver value to customers in a broad
range of industries. A unique combination of biology, chemistry,
software and automation enables the company to design and create
new materials.
Media ContactMike
Dulinmdulin@zymergen.com502-777-2029
Zymergen (NASDAQ:ZY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Zymergen (NASDAQ:ZY)
Historical Stock Chart
From Sep 2023 to Sep 2024